Stay updated on Pembrolizumab SubQ vs IV in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab SubQ vs IV in Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab SubQ vs IV in Melanoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded a new revision entry for v3.3.2 and removed v3.3.1 from the history. This updates the release version shown but does not affect study data or user-facing content.SummaryDifference0.1%

- Check21 days agoChange DetectedRevision: v3.3.1 was added and Revision: v3.2.0 was removed from the page history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check29 days agoChange DetectedNotice about a lapse in government funding and NIH operating status that previously appeared on the page has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check43 days agoChange DetectedA new version dated 2025-02-03 was added to the Record History, including updates to multiple sections such as Participant Flow, Baseline Characteristics, Outcome Measures, and Adverse Events.SummaryDifference0.2%

- Check71 days agoChange Detected- Added a prominent notice about potential outages due to lapse in government funding and updated operating status guidance. - Updated version from v3.1.0 to v3.2.0.SummaryDifference10%

- Check79 days agoChange DetectedReleased a new version tag (v3.1.0) replacing the old one (v3.0.2); core content and features are not shown to be affected.SummaryDifference0.3%

Stay in the know with updates to Pembrolizumab SubQ vs IV in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab SubQ vs IV in Melanoma Clinical Trial page.